WDNA WisdomTree BioRevolution ETF
WisdomTree BioRevolution USD

NAV as of 24-Mar-2023

16.6164

4 Week: 16.50 - 17.64

52 Week: 16.00 - 20.82

Latest Closing Price

16.73

Premium / Discount

0.02

Expense Ratio

0.45%

Investment Objective

The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (“index”). The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.

Main Fund Characteristics

Fund Manager:
WisdomTree
Asset Under Management:
2,654,994
Launch Date:
31/05/2021
Asset Class:
Equity
Replication Method:
Physical-Sample
Number of Holdings:
99
Trading Currency:
USD
Style:
Mid Blend
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
CBOEBZX

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-3.991.21-3.30
1 Day-0.400.000.00
1 Week-1.242.65-0.47
1 Month-3.085.96-0.52
3 Months-1.789.73-0.18
6 Months-3.2717.04-0.19
1 Year-16.9627.59-0.61
2 Years0.000.000.00
3 Years0.000.000.00
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2013201420152016201720182019202020212022
Price (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.0000-26.0556
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.00000.00000.000080.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
22/12/202228/12/20220.0653
26/12/202129/12/20210.0246

Portfolio Data

Total Number of Holdings: 99

Number of Bond Holdings: 0

Number of Equity Holdings: 99

Total Market Value: 2,654,994

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1AstraZeneca PLC ADR2.26221,416082,425

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant18.30
Large24.26
Medium31.76
Small11.47
Micro13.95

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

18.4702

Price/Book*

2.5991

Price/Sales*

2.2132

Price/Cash Flow*

11.3862

Dividend Yield*

1.0853

Growth Measures

Long-Term Earnings

7.5567

Historical Earnings

27.4076

Sales Growth

10.9424

Cash-Flow Growth

7.8594

Book-Value Growth

5.0339

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.